SEC-sourced researchBeta
NTLA
Intellia Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001652130
- Exchange
- Nasdaq
- Business activity
- — · SIC 2835
- Financial inputs
- 6/6
- Filing date
- Oct 6, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 36,275,000.0000 | Feb 26, 2026 |
| December 2024 | 57,877,000.0000 | Feb 26, 2026 |
| December 2025 | 67,671,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 67,671,000.0000 | -412,694,000.0000 | -394,736,000.0000 | 842,127,000.0000 | 170,733,000.0000 | Feb 26, 2026 |
| December 2024 | 57,877,000.0000 | -519,021,000.0000 | -348,880,000.0000 | 1,191,015,000.0000 | 319,059,000.0000 | Feb 26, 2026 |
| December 2023 | 36,275,000.0000 | -481,192,000.0000 | -394,086,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $67.67M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $57.88M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$412.69M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$394.74M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $842.13M | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $170.73M | December 2025 | Feb 26, 2026 | 10-K |